Evidence map›Paper›PMID 38682036›Full record

SynthesisFrontiers in neurology2024

Efficacy and efficacy-influencing factors of stem cell transplantation on patients with Parkinson's disease: a systematic review and meta-analysis.

Jianli Zhao, Kang Qu, Shanshan Jia, Rong Yang, Ziting Cui, Jiajia Li, Peng Yu, Ming Dong

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jianli ZhaoDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Kang QuDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Shanshan JiaDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Rong YangDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Ziting CuiDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Jiajia LiDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Peng YuDepartment of Ophthalmology, The Second Hospital of Jilin University, Changchun, China.
Ming DongDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cell transplants as a treatment for Parkinson's disease have been studied for decades, and stem cells may be the most promising cell sources for this treatment. We aimed to investigate whether stem cell transplantation contributes to the cure for Parkinson's disease and the factors that may influence the efficacy for this therapy. Methods: PubMed, Embase, Cochrane Library, Web of Science, SinoMed, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and ChinaInfo were thoroughly searched to find controlled trials or randomized controlled trials performing stem cell transplantation in patients with Parkinson's disease. The pooled effects were analyzed to evaluate the weighted mean difference (WMD) with 95% confidence intervals. Results: Nine articles were identified including 129 individuals. Stem cell transplantation was an effective treatment for Parkinson's disease (WMD = -14.86; 95% CI: -16.62 to -13.10; Conclusion: Data from controlled trials suggest that stem cell transplantation as a therapy for Parkinson's disease can be effective for at least 12 months. The factors that may influence its curative effect are time after transplantation and stem cell types. Systematic review registration: (Registration ID: CRD42022353145).

Indexed as

clinical trialmeta-analysisParkinsonstem celltransplantation

Identifiers

PMID38682036
PMCPMC11045895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.